Charles H.Arnett Ph.D. (Charlie)

IP Legal Intern

Washington + 1.202.879.3896

Charlie Arnett has scientific training in chemistry and an extensive background in synthetic organic and inorganic chemistry. His research background includes organic methodology, chemical kinetics, bioinorganic chemistry, and physical inorganic spectroscopy.

Prior to joining Jones Day, Charlie was an NSF Graduate Research Fellow at the California Institute of Technology, where he synthesized and studied model complexes of the nitrogenase active site. He also contributed to the development of a Cu-catalyzed protocol for C-H etherification as an undergraduate at Georgetown University and elucidated the mechanism of the transformation. Charlie has coauthored several peer-reviewed scientific publications, four of which are published in the Journal of the American Chemical Society.

Experience

  • Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitorsJones Day represents Nuvalent, Inc. in the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors for the treatment of cancer.